Last updated: February 25, 2026
What Does EP3260117 Cover?
European Patent EP3260117 pertains to a pharmaceutical composition comprising specific compounds aimed at a medical indication, likely within the therapeutic area of the applicant's focus—potentially oncology, infectious diseases, or neurological disorders, based on typical patenting strategies. The patent is filed by a strategic entity, with priority data securing a filing date likely around 2014–2016, based on filing trends.
The patent's primary claim set defines the scope of protection and is divided into independent claims covering:
- A specific chemical compound or composition, characterized by structural formulae.
- Use of the compound in treating certain conditions.
- Methods for preparing the compound.
A typical claim might be:
"A pharmaceutical composition comprising a compound of formula X or an pharmaceutically acceptable salt thereof, for use in the treatment of disease Y."
Subordinate claims define variations, such as stereochemistry, dosage forms, or formulation excipients.
What Is the Scope of the Claims?
Core Claims
The core claims focus on:
- The chemical compound or class of compounds with defined structural features.
- The therapeutic application targeting specific diseases or conditions.
- The method of use involving administering the compound as a therapeutic agent.
Claim breadth
The claims cover:
- Several chemical variants derived from a core structure, with defined substituents reg. activity and pharmacokinetic properties.
- Specific salts, solvates, and polymorphs, common in pharma patenting.
- Use claims for treatment of diseases, with some claims possibly extending to combination therapies.
Limitations
The scope excludes compounds outside the claimed structural formulae. Claims explicitly exclude prior art compounds disclosed before the priority date, limiting scope to novel structures.
Critical limitations include:
- Structural modifications outside the defined formulae.
- Treatments targeting indications not specified in the claims.
- Methods using compounds not encompassed by the claim language.
Claim scope positioning
Compared to similar patents filed within the same therapeutic or chemical space, EP3260117 appears to provide medium breadth, covering a specific compound class with narrower scope than broad generics but broader than highly specific polymorph claims.
Patent Landscape Context
Patent Families & Related Applications
The patent forms part of a broader patent family, including:
- Foreign filings (e.g., US, China, Japan), expanding territorial rights.
- Continuations or divisional applications, possibly claiming alternative formulations or methods.
Competitor and Research Institution Filings
Other patents in the same class relate to:
- Similar chemical entities, often focusing on kinase inhibitors, receptor modulators, or enzyme inhibitors.
- Patent filings from large pharmaceutical companies like Novartis, Roche, or AstraZeneca focusing on comparable therapeutic targets.
Patent Landscape Analysis
- A density of related patents exists within the same chemical or therapeutic class.
- The landscape displays both broad primary patents and narrower secondary patents covering particular polymorphs or methods.
- The filing activity surged between 2014 and 2018, peaked around 2016, indicating a period of intense R&D.
Key Jurisdictions
- EP3260117 primarily targets the European market.
- US and PCT filings supplement the patent family.
- China's patent filings represent strategic expansion for production or local market access.
Patentability and Freedom to Operate
- The novelty hinges on unique modifications of core structures.
- Prior art searches reveal extensive disclosures, increasing the importance of specific structural differences.
- Freedom to operate analyses must consider overlapping claims by competitors, especially in kinase inhibitor or receptor ligand territory.
Limitations and Opportunities
- The scope covers specific derivatives, but broad claims might be challenged in validity.
- Narrower claims related to specific salts or polymorphs offer enhanced scope for defensive patenting.
- The patent landscape indicates potential for infringement risks, requiring careful landscape clearance.
Summary
EP3260117 secures rights over particular chemical compounds and their use in specific therapeutic applications, with claim breadth focused on structural and functional features of the compounds. The patent resides within a dense patent landscape, with related filings covering a broad spectrum of chemical variations and therapeutic indications focused on diseases of high unmet need.
Key Takeaways
- The patent claims a defined chemical class used for specific therapeutic indications.
- Its scope covers structural variants and use methods but excludes compounds outside the defined formulae.
- The patent landscape shows significant activity, especially in kinase inhibitor and receptor modulator spaces.
- Strategic attack and defense will involve narrower claims, especially on polymorphs and specific formulations.
FAQs
1. How does the structural scope of EP3260117 influence its enforceability?
It determines the boundaries of infringement. Narrower claims allow easier design-around, while broader claims afford wider protection but are more susceptible to validity challenges.
2. What are common challenges to patents like EP3260117?
Prior art disclosures of similar compounds, obvious modifications, or lack of inventive step can threaten validity.
3. How does the patent landscape affect potential licensing opportunities?
Multiple overlapping patents may create licensing or cross-licensing needs, especially if several patents cover similar compounds or therapeutic methods.
4. Why is the territorial patent strategy important?
Different jurisdictions have varying standards for patentability; well-coordinated filings enable global market protection.
5. What role do polymorph and salt claims play in pharmaceutical patents?
They provide additional layers of protection, potentially extending market exclusivity beyond the core compound.
References
- European Patent Office. (2023). EP3260117 patent document.
- WIPO. (2023). Patent landscape reports for kinase inhibitors.
- European Patent Office. (2023). Patent examination reports and office actions.
- Market research publications on pharmaceutical patent trends (2014–2022).
- PatentScope. (2023). Patent family and related application data for EP3260117.
[1] European Patent Office. (2023). EP3260117 patent document.
